Talphera said its NEPHRO CRRT study has reached 75% enrollment and remains on track to complete enrollment later this year. CEO Vincent Angotti said the estimated annual CRRT procedures in 2027 are approximately 200,000 in the United States, with about 70 institutions representing over 50% of those procedures. CFO Raffi Asadorian said cash at June 30, 2026, was $17.1 million, with two conditional financing tranches remaining totaling approximately $16 million of additional capital. Management expects top-line data about 4 weeks after enrollment completes and a PMA filing about 3 months later, targeting the first half of next year.
Talphera Inc.NEPHRO CRRT study enrollment progress and expected PMA filing indicate advancement of its product.
